Intraperitoneal chemotherapy
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | IS THERE A CLEAR RATIONALE FOR THE USE OF INTRAPERITONEAL THERAPY, IN PARTICULAR INTRAPERITONEAL CHEMOTHERAPY IN OVARIAN CANCER? Yes. Intraperitoneal (IP) chemotherapy for the treatment of patients with epithelial ovarian cancer is theoretically an attractive approach, taking into account the biology of the disease, the physiologic and anatomic characteristics of the peritoneal cavity, and the pharmacologic advantage of several anticancer agents, when administered IP compared to intravenously (IV)1. Its theoretical advantages consist of (i) the possibility that high local drug concentrations may penetrate into small tumor nodules and overcome the "apparent" drug resistance of cells, (ii) the possibility that prolonged exposure time may enhance the activity of certain classes of drugs, and (iii) systemic toxicities may be reduced, allowing greater tolerance of treatment. |